Status:
COMPLETED
Post-marketing Study to Collect Safety Data in Heart Transplant Patients Receiving Everolimus
Lead Sponsor:
Novartis
Conditions:
Coronary Heart Disease
Eligibility:
All Genders
18-65 years
Brief Summary
The purpose of this observational protocol is to evaluate the use of everolimus in routine clinical practice for heart transplants. Primary outcome measures: incidence of acute rejection episodes Sec...
Eligibility Criteria
Inclusion
- Cardiac transplant recipients
- Discharged alive from hospital
- Must be receiving everolimus
Exclusion
- Patients not treated with everolimus beginning within 2 weeks after receiving a heart transplant
- Other inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
January 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2006
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00134940
Start Date
January 1 2005
End Date
November 1 2006
Last Update
June 16 2011
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Novarits
Graz, Austria
2
Novartis Investigative Site
Innsbruck, Austria
3
Novartis
Wein, Austria
4
Novartis
Bad Oeynhausen, Germany